MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq: BDSI) has hired David Blum, M.D. as Vice President of Medical Affairs and Clinical Research, a newly created position, effective September 4, 2007. In this role, Dr. Blum is responsible for the design, conduct, analysis and reporting of all clinical research studies required to support additional claims for the Company’s Phase III BEMATM Fentanyl product and the development of other products in the Company’s portfolio, including BEMA LA and Bioral® Amphotericin B.
